LivingGLP1
Study S000319

A Phase 1 Study of Liraglutide Injection and Victoza® in Healthy Chinese Subjects: An Open, Randomized, Single-Dose and Crossover Study

ClinicalTrials.gov record

Registration

Registration
NCT05225974
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1
Masking
NONE
Status
COMPLETED
Enrollment
32
Start
2021-07-16
Primary completion
2021-07-30
Lead sponsor
The Affiliated Hospital of Qingdao University
Conditions
Therapeutic Equivalency
Interventions
DRUG:Liraglutide injection; DRUG:Liraglutide injection(Victoza®)
Results posted
FALSE

Registered primary outcomes

  • Peak Plasma Concentration (Cmax) [40 days]
  • Area under the plasma concentration versus time curve (AUC)0-t [40 days]
  • Area under the plasma concentration versus time curve (AUC)0-∞ [40 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.